SCHEMBL2811189

SCHEMBL2811189

CCC1=CCc2ccccc2[CH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
SETD7 Q8WTS6 2/20 0.34
TP53 P04637 2/20 0.33
ABCB11 O95342 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
HTR1A P08908 1/20 0.33
CHRM5 P08912 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2D6 P10635 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD2 P14416 1/20 0.33
TSHR P16473 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
CHRM3 P20309 1/20 0.33
DRD1 P21728 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4309882 0.85 CA1 (0.36) CA1CA2ALDH1A1DRD3MEN1
SCHEMBL5065423 0.82 CYP2D6 (0.34) CA1CA2SETD7ALDH1A1CYP1A2
SCHEMBL5025282 0.79 LIPG (0.40) SETD7ALDH1A1CYP1A2CYP2D6DRD2
SCHEMBL5285345 0.76 CA1 (0.35) CA1CA2DRD2ADRA1DADRA1A
SCHEMBL1115535 0.73 ALDH1A1 (0.38) CA1CA2TP53ALDH1A1HTR2A
SCHEMBL1923119 0.72 CA1 (0.46) CA1CA2CYP1A2TSHRHTR2C
SCHEMBL1958676 0.72 CA1 (0.41) CA1CA2
SCHEMBL8680912 0.70 ADRA2A (0.42) ALDH1A1CYP1A2HTR1AADRA2ACYP2D6
SCHEMBL4306921 0.69 HTR2C (0.33) CA1CA2TP53ALDH1A1TSHR
SCHEMBL3348711 0.68 CA1 (0.41) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680278-B2 Enantioselective process for preparing a substituted alkanoic acid JANSSEN PHARMACEUTICA NV (BE) 2014-03-25 US disclosed
US-8293864-B2 Metal thietane compound, polymerizable composition containing the compound, resin and use of the resin MITSUI CHEMICALS, INC. (JP) 2012-10-23 US disclosed
US-20100240862-A1 METAL THIETANE COMPOUND, POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND, RESIN AND USE OF THE RESIN MITSUI CHEMICALS, INC. (JP) 2010-09-23 US disclosed
US-20090124804-A1 Enantioselective process for preparing a substituted alkanoic acid JANSSEN PHARMACEUTICA NV (BE) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240862-A1 METAL THIETANE COMPOUND, POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND, RESIN AND USE OF THE RESIN TERB1, TPR, TBXAS1 CA1 917/4885CA2 1482/4885SETD7 1256/4885
US-20090124804-A1 Enantioselective process for preparing a substituted alkanoic acid ITGA5, ITGA1, ITGB5 CA1 1952/4885CA2 1259/4885SETD7 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.